Shi­madzu Cor­po­ra­tion es­tab­lish­es three R&D cen­ters in the US in an­tic­i­pa­tion of busi­ness ex­pan­sion for phar­ma­ceu­ti­cal com­pa­nies

Japan’s Shi­madzu Cor­po­ra­tion an­nounced this month that its US sub­sidiary, Shi­madzu Sci­en­tif­ic In­stru­ments (SSI), has es­tab­lished a new R&D cen­ter in the US, and is plan­ning to strength­en its prod­uct de­vel­op­ment ca­pa­bil­i­ties and tech­nol­o­gy for its work with phar­ma­ceu­ti­cal com­pa­nies.

The R&D cen­ter con­sists of the Mary­land head­quar­ters at­tached to the SSI head­quar­ters, and new lo­ca­tions near Boston and San Fran­cis­co that will work on pro­to­types de­vel­oped with the com­pa­ny’s cus­tomers. The com­pa­ny’s Mary­land head­quar­ters will in­clude a col­lab­o­ra­tion lab to con­duct joint re­search with cus­tomers.

Shi­madzu Cor­po­ra­tion says it plans to in­crease par­ent com­pa­ny Shi­madzu Group’s sales in North Amer­i­ca from 51 bil­lion yen ($330 mil­lion) in 2022 to over 70 bil­lion yen ($452 mil­lion) in 2025 by lever­ag­ing SSI’s bases to ex­pand its busi­ness to phar­ma­ceu­ti­cal com­pa­nies.

Endpoint News

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

“We will work close­ly with phar­ma­ceu­ti­cal com­pa­nies to as­sess their needs and pro­ceed with the de­vel­op­ment of prod­ucts (such as an­a­lyt­i­cal and mea­sur­ing in­stru­ments). In ad­di­tion to the small mol­e­cule drugs that SSI has pre­vi­ous­ly col­lab­o­rat­ed with phar­ma­ceu­ti­cal com­pa­nies on, we will al­so con­tribute to the de­vel­op­ment of bio­phar­ma­ceu­ti­cals,” said a Shi­madzu spokesper­son.

This ar­ti­cle was writ­ten by Nori­ka Ya­ma­ji.

First published with our partner Nikkei Biotechnology & Business here.